Northpond Ventures

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The company provides a digital solution that consolidates data and knowledge from various teams into a single, searchable cloud-based hub. This integrated platform streamlines product, process, and quality workflows, allowing organizations to enhance their technical success rates and expedite the delivery of therapeutic innovations to patients. By offering tools for managing development processes, risk evaluation, and data analytics, QbDVision addresses the inefficiencies and data integrity challenges often present in legacy software systems. As organizations utilize this platform, they gain a comprehensive view of their product life cycles, enabling informed decision-making and improved control over development processes.

EnPlusOne Biosciences specializes in developing an enzymatic-based RNA synthesis platform designed to overcome limitations of traditional chemical synthesis methods. Their innovative approach aims to facilitate large-scale production and expand accessibility to diverse nucleotide modifications for emerging RNA therapeutics.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Telesis Bio is a biotechnology company founded in 2013 and based in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, create, and secure synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible synthesis of high-quality synthetic genetic materials for various applications in synthetic biology. Telesis Bio manufactures and sells a range of laboratory equipment, including synthetic biology instruments and reagents, as well as offering related services. Its product lineup features the BioXp system, BioXp kits, and Benchtop reagents, alongside BioXp biofoundry services, all aimed at supporting innovative research and development in the field.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

Opna Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics. The company focuses on creating new drugs that target the hallmarks of cancer, particularly addressing immune suppression mechanisms that contribute to cancer cell growth. By developing therapies that aim to disrupt these processes, Opna Bio seeks to provide physicians with more effective treatment options for cancer patients, thereby advancing the standard of care in oncology.

EnPlusOne Biosciences specializes in developing an enzymatic-based RNA synthesis platform designed to overcome limitations of traditional chemical synthesis methods. Their innovative approach aims to facilitate large-scale production and expand accessibility to diverse nucleotide modifications for emerging RNA therapeutics.

Vestaron develops and manufactures peptide-based biologic crop protection products. Its offerings include Spear-T for thrips control in greenhouses, Spear-Lep for fruits and vegetables, and Leprotec for field use. Headquartered in Durham, North Carolina with a research center in Kalamazoo, Michigan, Vestaron aims to provide growers with effective, safe, and sustainable biopesticides.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Vestaron develops and manufactures peptide-based biologic crop protection products. Its offerings include Spear-T for thrips control in greenhouses, Spear-Lep for fruits and vegetables, and Leprotec for field use. Headquartered in Durham, North Carolina with a research center in Kalamazoo, Michigan, Vestaron aims to provide growers with effective, safe, and sustainable biopesticides.

Founded in 2018, Ansa Biotechnologies develops an innovative DNA synthesis technology based on enzymes. This novel approach aims to accelerate biological research and engineering by producing gene-length oligonucleotides more efficiently than traditional chemical methods.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Walking Fish Therapeutics is focused on developing innovative cell-based therapeutics aimed at treating serious diseases, particularly in the fields of oncology and regenerative medicine. The company leverages the unique capabilities of B cells to activate the immune system, thereby creating treatments for cancer and other conditions. Additionally, these B cell factories can function as in vivo protein producers, generating replacement proteins for deficiency diseases and engineered antibodies. By harnessing locally acting proteins, Walking Fish Therapeutics seeks to enhance therapeutic outcomes and provide targeted solutions for patients suffering from various ailments.

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The company provides a digital solution that consolidates data and knowledge from various teams into a single, searchable cloud-based hub. This integrated platform streamlines product, process, and quality workflows, allowing organizations to enhance their technical success rates and expedite the delivery of therapeutic innovations to patients. By offering tools for managing development processes, risk evaluation, and data analytics, QbDVision addresses the inefficiencies and data integrity challenges often present in legacy software systems. As organizations utilize this platform, they gain a comprehensive view of their product life cycles, enabling informed decision-making and improved control over development processes.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

64x Bio develops a platform that accelerates and scales mammalian cell line discovery. It combines high-throughput screening with computational design loops to create optimized cell lines for viral vector production, focusing on those used in cell and gene therapies.

Ori Biotech develops a manufacturing platform designed to accelerate the production of cell and gene therapies. Its proprietary system automates and standardizes manufacturing processes, enabling therapeutics developers to efficiently bring lifesaving treatments to patients.

Scitara is a global provider of cloud-based software solutions tailored for scientific laboratories. Its platform enables modern lab data connectivity infrastructure and tools, accelerating scientific research by enhancing efficiency and reducing errors.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

Kytopen Corp., founded in 2017, develops proprietary Flowfect™ technology for non-viral delivery of molecules into hard-to-transfect immune cells. Its platform combines microfluidics and automation to facilitate efficient cell engineering.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Vestaron develops and manufactures peptide-based biologic crop protection products. Its offerings include Spear-T for thrips control in greenhouses, Spear-Lep for fruits and vegetables, and Leprotec for field use. Headquartered in Durham, North Carolina with a research center in Kalamazoo, Michigan, Vestaron aims to provide growers with effective, safe, and sustainable biopesticides.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Scitara is a global provider of cloud-based software solutions tailored for scientific laboratories. Its platform enables modern lab data connectivity infrastructure and tools, accelerating scientific research by enhancing efficiency and reducing errors.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Founded in San Diego, California in 2015, Encodia specializes in proteomics research. It develops scalable and parallelized approaches to protein analysis, aiming to accelerate novel disease treatments through personalized medicine.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

NanoView Diagnostics develops the ExoView platform for characterizing extracellular vesicles through specific binding and detection on an affinity microarray. Its products include ExoView R100, ExoView Tetraspanin kits, custom assays, sample services, and support.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

ArtisanBio is a developer of cell engineering and data analysis solutions aimed at advancing cell therapies for various human health applications. The company's innovative platform allows partners to optimize candidate designs for cell therapies, enhancing their safety and efficacy. By focusing on rapid discovery, performance in editing, and data analytics, ArtisanBio provides customizable solutions that address the complexities of next-generation cellular therapies. Through strategic collaborations with other innovators, ArtisanBio seeks to facilitate the development and delivery of precision-engineered cells, ultimately supporting healthcare providers in generating effective therapeutic options.

Refeyn Ltd develops and commercializes mass photometry technology for measuring the mass of single biomolecules in solution. The company offers instruments and accessories, including Refeyn One, which uses single-molecule light scattering to detect, image, and determine the mass of biomolecules in their native, unlabeled state. Its technology provides both research-grade tools and quality-control instruments for measuring biomolecules across a range of concentrations, enabling label-free mass measurement of individual molecules. Founded in 2018 and based in Oxford, United Kingdom, Refeyn focuses on delivering precise, rapid mass analysis to researchers studying proteins, nucleic acids, and other biomolecules.

Ori Biotech develops a manufacturing platform designed to accelerate the production of cell and gene therapies. Its proprietary system automates and standardizes manufacturing processes, enabling therapeutics developers to efficiently bring lifesaving treatments to patients.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Deep Lens, Inc. is a technology company based in Columbus, Ohio, focused on enhancing the field of digital pathology and cancer research. Founded in 2017, it offers a comprehensive workflow platform known as VIPER, which integrates artificial intelligence for image detection, collaboration, and cloud storage. The platform supports pathology groups by facilitating collaboration on cancer research and includes features such as workflow management, built-in APIs for third-party AI model integration, and compatibility with electronic medical records and laboratory information management systems. By leveraging AI and machine learning, Deep Lens aims to optimize patient treatment options and improve the efficiency of clinical trial enrollment in oncology, ultimately enhancing patient care and advancing research in precision therapies.

Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative cancer immunotherapies aimed at improving the lives of cancer patients and their families. The company specializes in viral immunotherapies that utilize genetically modified adenoviruses and herpes simplex virus constructs to target cancer effectively. Candel's approach focuses on preventing the recurrence and progression of cancer with low toxicity, making it particularly suitable for treating less aggressive or slower-growing cancers, such as newly diagnosed prostate cancer. By enhancing treatment outcomes and facilitating faster recovery for patients, Candel Therapeutics strives to make a meaningful impact in the field of oncology.

Founded in 2015, Teckro is a life science technology company based in Limerick, Ireland. It offers a solution that transforms clinical trials by instantly connecting all relevant stakeholders and sharing knowledge, reducing burden on study personnel. The company serves pharmaceutical companies and clinical researchers globally.

NanoView Diagnostics develops the ExoView platform for characterizing extracellular vesicles through specific binding and detection on an affinity microarray. Its products include ExoView R100, ExoView Tetraspanin kits, custom assays, sample services, and support.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.